In August 2022, PARP inhibitors were approved for the indication of "postoperative pharmacological treatment of BRCA mutation-positive, HER2-negative breast cancer at high risk of recurrence," and BRCA genetic testing as a companion diagnostic was additionally covered by insurance. Here, ERBB2 is linked to breast carcinoma.